Stocks · News reference
Tango Therapeutics and Erasca have provided an update regarding their ongoing Phase 1/2 clinical study of an oral PRMT5 inhibitor.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Tango Therapeutics announced that its President and CEO, Malte Peters, M.D., will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026.
Tango Therapeutics reported positive clinical data from its Phase 1/2 study of vopimetostat in combination with daraxonrasib for patients with metastatic pancreatic ductal adenocarcinoma.
Filed: 2026-10-23 AccNo: 0001193125-26-429423 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
William Blair analyst Alethia Young initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Outperform rating.
Tango Therapeutics announced it will present updated Phase 1/2 study data on vopimetostat combined with daraxonrasib or zoldonrasib for treating MTAP-deleted RAS-mutant metastatic pancreatic and lung cancers at the ESMO Congress 2026 in Madrid. The company will also host a PDAC-focused investor webcast on October 23, 2026.
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present